## **SUPPLEMENTARY FIGURES**

Contents:

Figure S1. Catalytic mechanism of the dipeptide epimerases.

Figure S2. Selected alignments used for generating homology models. Catalytic Lys residues are in red, the DxD motif in green, and the position corresponding to Arg24 in 1TKK (which coordinates the Glu side chain of the Ala-Glu ligand) in red.

Figure S3. Sequence similarity network showing the distribution of bacterial, archaeal, and eukaryotic sequences.

Figure S4. L-Ala-L-Glu modeled in the binding site of a homology model for XP\_002649142, a predicted dipeptide epimerase from *Dictyostelium discoideum*.

Figure S5. Binding site of the dipeptide epimerase from *E. faecalis*, bound to (a) inorganic sulfate, (b) L-Leu-L-Tyr, (c) L-Ser-L-Tyr, and (d) L-Arg-L-Tyr.

Figure S6. Binding site of the dipeptide epimerase from *B. thetaiotamicron*, bound to (a) L-Ala-D-Glu and (b) L-Pro-D-Glu.

Figure S7. Binding site of the dipeptide epimerase from *C. hutchinsonii*, bound to D-Ala-L-Val (3Q45).

Figure S8. Binding site of the dipeptide epimerase from *M. capsulatus* in the apo state (3RO6).

Figure S9. Binding site of the dipeptide epimerase from *H. aurantiacus* in the apo state (3IK4).

Figure S10. Binding site of the dipeptide epimerase from *F. philomiragia*, (a) with only  $Mg^{2+}$ bound, (b) in complex with fumarate, (c) in complex with tartrate, and (d) in complex with tartrate, with no  $Mg^{2+}$  bound.

Figure S11. Superposition of representative structures of the dipeptide epimerases with varying specificities.

Figure S12. Comparisons of computationally predicted (purple) and experimentally determined (green) structures of dipeptide epimerases in complex with dipeptide substrates.



Figure S1. Catalytic mechanism of the dipeptide epimerases. In all cases, the enzyme side chains responsible for protonation and deprotonation are Lys. Here, deuterium is shown being incorporated, as in the mass spectroscopy screening assay. The carboxylate is coordinated to the required magnesium ion.

B.subtilis E.coli B.thetaiotaomicron ----------------------------------- MPNRRDFLKTAAFATLGSGI E.faecalis  $c.$ hutchinsonii M.capsulatus **B.subtilis** E.coli B.thetaiotaomicron AVSOVLAGECMPSAIHINKYGIGGKMKMTFFPYELKLRHVFTVATYSRTTTPDV E.faecalis  $C.$ hutchinsonii M.capsulatus **B.subtilis** IVRITYDSGAVGWGEAPPTLVITGDSMDSIESAIHHVLKPALL-GK-SLAGYEA E.coli VVELEEE-GIKGTGECTPYP-RYGESDASVMAQIMS-VVPQLE-KGL--B.thetaiotaomicron OVEIEYE-GVTGYGEASMPP-YLGETVESVMNFLKKVNLEOFS----DPFOLED E.faecalis IVEIETEEGLVGYGEGGPGIFITGETLAGTLETIE-LFGOAII-GL-NPFNIEK C.hutchinsonii IVRIHTASGHIGYGECSPFMTIHGESMDTAFIVGOY-LAKGLI-GT-SCLDIVS M.capsulatus IVEIRTADGLLGLGAASPERHVTGETLEACHAALDH-DRLGWLMGR-DIRTLPR  ${\tt ILHDIQHLLTGMNAKAAVEMALYDGWAQMCGLPLYQMLGG-YRDTLETDYTVS}$ **B.subtilis** E.coli TREELQKIL-PAGAARNALDCALWDLAARKQQQSLADLIGITLPETVTTAQTIV B.thetaiotaomicron ILSYVDSLSPKDTAAKAAVDIALHDLVGKLLGAPWYKIWGLNKEKTPSTTFTIG E.faecalis IHEVMDKISAFAPAAKAAIDIACYDLMGQKAQLPLYQLLGG-YDNQVITDITLG C.hutchinsonii NSLLMDAIIYGNSCIKSAFNIALYDLAAOHAGLPLYAFLGGKKDKIIOTDYTVS M.capsulatus LCRELAERLPAAPAARAALDMALHDLVAOCLGLPLVEIL-GRAHDSLPTSVTIG VNSPEEMAADAENYLKQGFQTLKIKVGK--DDIATDIARIQEIRKRVGSAVKLR **B.subtilis**  ${\tt E. coli}$ IGTPDQMANSASTLWQAGAKLLKVKLDNHL-----ISERMVAIRTAVP-DATLI B.thetaiotaomicron IDTPDVVRAKTKECAGL-FNILKVKLGRDN-----DKEMIETIRSVT--DLPIA  $\label{thm:main} \begin{minipage}[c]{0.9\textwidth} \begin{min$ E.faecalis  $\mathtt{C}.\mathtt{hutchinsonii}$ M.capsulatus IKPVEETLAEAREHLALGFRVLKVKLCG---DEEQDFERLRRLHETLAGRAVVR LDANOGWRP-KEAVTAIRKMEDAGLGIELVEOPVHKDDLAGLKKVTDATDTPIM **B.subtilis** VDANESWRA-EGLAARCQLLAD--LGVAMLEQPLPAQDDAALENF--IHPLPIC E.coli VDANQGWKDRQYALDMIHWLKE--KGIVMIEQPMPKEQLDDIAWVTQQSPLPVF B.thetaiotaomicron E.faecalis LDANQAWTP-KDAVKAIQALAD--YQIELVEQPVKRRDLEGLKYVTSQVNTTIM  $C.$ hutchinsonii IDANQGWSV-ETAIETLTLLEP--YNIQHCEEPVSRNLYTALPKIRQACRIPIM M.capsulatus VDPNQSYDR-DGLLRLDRLVQE--LGIEFIEQPFPAGRTDWLRALPKAIRRRIA B.subtilis ADESVFTPRQAFEVLQT-RSADLINIKLMKAGGISGAEKINAMAEACGVECMVG ADESCHTRSNLKALK---GRYEMVNIKLDKTGGLTEALALATEARAOGFRLMLG E.coli ADESLORLGDVAALK---GAFTGINIKLMKCTGMREAWKMVTLAHALGMRVMVG B.thetaiotaomicron ADESCFDAQDALELVKK-GTVDVINIKLMKCGGIHEALKINQICETAGIECMIG E.faecalis C.hutchinsonii ADESCCNSFDAERLIQI-QACDSFNLKLSKSAGITNALNIIRLAEQAHMPVQVG M.capsulatus ADESLLGPADAFALAAPPAACGIFNIKLMKCGGLAPARRIATIAETAGIDLMWG **B.subtilis** SMI-ETKLGITAAAHFAASKRNITRFDFDAPLMLKTDVFNGGITYSG--STISM E.coli CML-CTSRAISAAL-PLV-PO-VSFADLDGPTWLAVDV-EPALOFTT--GELHL CMT-ETSCAISAAS-QFS-PA-VDFADLDGNLLISNDR-FKGVEVVN--GKITL B.thetaiotaomicron CMAEETTIGITAAAHLAAAQKNITRADLDATFGLETAPVTGGVSLEAK-PLLEL E.faecalis  $C.$ hutchinsonii GFL-ESRLGFTAAAHVALVSKTICYYDFDTPLMFEADPVRGGIVYQQ-RGIIEV M.capsulatus CMD-ESRISIAAALHAALACPATRYLDLDGSFDLARDVAEGGFILED--GRLRV **B.subtilis** PGKPGLGIIGAAL-LKGEKEQ---E.coli B.thetaiotaomicron NDLPGIGVMKI-------------GEAAGLGISH--------------E.faecalis  ${\tt C.hutchinsonii}$ PETAGLGAGYQKDYLSGLEKICIN M.capsulatus TERPGLGLVYPD------------

Figure S2. Selected alignments used for generating homology models. Catalytic Lys residues are in red, the DxD motif in green, and the position corresponding to Arg24 in 1TKK (which coordinates the Glu side chain of the Ala-Glu ligand) in red.



Figure S3. Sequence similarity network showing the distribution of bacterial, archaeal, and eukaryotic sequences. The network is constructed as in Figures 1 and 2.



Figure S4. L-Ala-L-Glu modeled in the binding site of a homology model for XP\_002649142, a predicted dipeptide epimerase from *Dictyostelium discoideum*. This sequence has not been experimentally characterized.



Figure S5. Binding site of the dipeptide epimerase from *E. faecalis*, bound to (a) inorganic sulfate, (b) L-Leu-L-Tyr, (c) L-Ser-L-Tyr, and (d) L-Arg-L-Tyr. The dipeptide and selected active site residues are shown in stick representation.



Figure S6. Binding site of the dipeptide epimerase from *B. thetaiotamicron*, bound to (a) L-Ala-D-Glu and (b) L-Pro-D-Glu. Both ligands are bound in a non-catalytically productive conformation, in which the carboxylate group is not in direct contact with the metal ion.



Figure S7. Binding site of the dipeptide epimerase from *C. hutchinsonii*, bound to D-Ala-L-Val (3Q45).



Figure S8. Binding site of the dipeptide epimerase from *M. capsulatus* in the apo state (3RO6).



Figure S9. Binding site of the dipeptide epimerase from *H. aurantiacus* in the apo state (3IK4). The metal ion is  $K^+$ , not  $Mg^{2+}$  as required for catalysis.



Figure S10. Binding site of the dipeptide epimerase from *F. philomiragia*, (a) with only  $Mg^{2+}$ bound, (b) in complex with fumarate, (c) in complex with tartrate, and (d) in complex with tartrate, with no  $Mg^{2+}$  bound.



Figure S11. Superposition of representative structures of the dipeptide epimerases with varying specificities, from *B. subtilis* (1TKK, white); *B. thetaiotamicron* (3IJQ, magenta); *E. faecalis* (3JW7, cyan); *C. hutchinsoni* (3Q4D, yellow); *M. capsulatus* (3RIT, red); and *F. philomiragia* (3R1Z, blue). The pairwise  $C\alpha$  RMSD's are 1.1 Å or less.



Figure S12. Comparisons of computationally predicted (purple) and experimentally determined (green) structures of dipeptide epimerases in complex with dipeptide substrates. The stereochemistries of the computationally predicted ligands are all L amino acids. The stereochemistries assigned to the co-crystallized ligands are detailed in Table 2.

## **SUPPLEMENTARY TABLES**

- Table S1: Information about homology models.
- Table S2: Dipeptide epimerases characterized *in vitro*.
- Table S3. Screening results with the L-Ala-L-Xxx library.
- Tables S4-S20: Complete results from the mass spectroscopy based assays.
- Tables S21-S25: Complete kinetic results obtained for selected dipeptide epimerases.
- Tables S26-S31: Data collection and refinement statistics for all determined crystal structures.

Table S1: Information about homology modeled sequences, organized according to predicted specificity classes: organisms, sequence identity to the *Bacillus subtilis* template structure (1TKK), RMSDs between the model and the crystal structure, in cases where a structure was subsequently obtained.







(a) zdope score (http://modbase.compbio.ucsf.edu/evaluation/).

(b) The two groups of predicted Ala-Hyd dipeptide epimerases were phylogenetically distinct but each was assigned the same predicted specificity; we have merged them into one specificity group in Figure 1 for simplicity.



Table S2: Dipeptide epimerases characterized *in vitro*.

Table S3. Screening results with the L-Ala-L-Xxx library. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



 $\overline{1}$  $<sup>1</sup>$  Full species names and gi numbers of the sequences are provided in Supplementary Table</sup> S2.

Table S4. Mass spectroscopy screening data for the dipeptide epimerase from bacterium Ellin514. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S5. Mass spectroscopy screening data for the dipeptide epimerase from Sulfurimonas denitrificans DSM 1251. Deuterium incorporation was measured at 16 hours after incubation. " $++$ " indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.

	Gly- L-Xxx	L-Ala- L-Xxx	L-Xxx- L-Glu
Gly			$\pmb{++}$
Ala			$\pmb{++}$
Ser			$\pmb{++}$
Pro			$\pmb{++}$
Val			$\pmb{++}$
Thr		$\hspace{0.1mm} +$	$\pmb{++}$
Leu/lle			$\boldsymbol{+}$
Asn			$\mathrm{+}$
Asp			
Lys			
Gln	$\ddagger$		
Glu	$\ddagger$	$\!+\!$	
Met		$\pm$	$\pmb{++}$
His			
Phe			$\pmb{++}$
Arg			
Tyr			$\pm$
<b>Trp</b>			$\hspace{.1cm} + \hspace{.1cm}$

Table S6. Mass spectroscopy screening data for the dipeptide epimerase from Campylobacterales *bacterium*. Deuterium incorporation was measured at 16 hours after incubation. " $++$ " indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.

	Gly- L-Xxx	L-Ala- L-Xxx	L-Xxx- L-Asp	L-Xxx- L-Glu
Gly				
Ala				$\pmb{++}$
Ser				
Pro				$\boldsymbol{+}\boldsymbol{+}$
Val				$\pm$
Thr				$\hspace{0.1mm} +$
Leu/lle				$\ddagger$
Asn				
Asp				
Lys			$\ddag$	
Gln		$\ddagger$		
Glu	$\ddagger$	$\boldsymbol{+}\boldsymbol{+}$		
Met		$\ddagger$		$\ddagger$
His				
Phe				$\hspace{0.1mm} +$
Arg			$\hspace{0.1mm} +$	
Tyr				
Trp				

Table S7. Mass spectroscopy screening data for the dipeptide epimerase from *Herpetosiphon aurantiacus*  ATCC 23779. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.

	Gly- $L-Xxx$	L-Ala- $L-Xxx$	L-Xxx- L-Ala	L-Xxx- L-Ile	L-Xxx- L-Leu	L-Xxx- L-Tyr	L-Xxx- L-Phe	L-Xxx- L-Asp	L-Xxx- $L$ -Glu
Gly			$\boldsymbol{++}$	$+$	$\pm$				
Ala	$\boldsymbol{++}$	$\boldsymbol{++}$	$\!+\!$	$+$	$\boldsymbol{++}$	$\boldsymbol{+}\boldsymbol{+}$	$\pmb{+}\pmb{+}$		
Ser	$\boldsymbol{++}$	$\boldsymbol{++}$				$\ddagger$			
Pro									
Val	$\boldsymbol{++}$	$\boldsymbol{++}$				$\boldsymbol{+}\boldsymbol{+}$	$\boldsymbol{+}\boldsymbol{+}$		
Thr	$\boldsymbol{+}\boldsymbol{+}$	$\pmb{+}\pmb{+}$					$\boldsymbol{+}$		
Leu/Ile	$\boldsymbol{++}$	$\boldsymbol{++}$				$\ddagger$	$\boldsymbol{+}$		
Asn									
Asp									
Lys									
Gln									
Glu									
Met	$\boldsymbol{++}$	$\boldsymbol{++}$			$\ddagger$	$\boldsymbol{++}$	$\pmb{++}$		
His									
Phe	$\ddagger$	$\boldsymbol{+}$	$\ddag$		$\pm$	$\boldsymbol{++}$	$\pmb{++}$		
Arg									
Tyr	$+$	$\boldsymbol{++}$	$\boldsymbol{+}$		$\pm$	$\boldsymbol{++}$	$\boldsymbol{+}\boldsymbol{+}$		
Trp	$\ddagger$	$\dagger$	$\boldsymbol{++}$		$\ddagger$	$\ddagger$	$\ddagger$		

Table S8. Mass spectroscopy screening data for the dipeptide epimerase from *Methylococcus capsulatus.* Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S9. Mass spectroscopy screening data for the dipeptide epimerase from Desulfobacterium autotrophicum. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S10a. Mass spectroscopy screening data for the dipeptide epimerase from *Geobacter bemidjiensis*  Bem. Specificity for C-terminal position. Deuterium incorporation was measured at 16 hours after incubation, unless otherwise specified. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S10b. Mass spectroscopy screening data for the dipeptide epimerase from *Geobacter bemidjiensis*  Bem. Specificity for N-terminal position. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S11. Mass spectroscopy screening data for the dipeptide epimerase from *Francisella philomiragia*  subsp. philomiragia ATCC 25017. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S12. Mass spectroscopy screening data for the dipeptide epimerase from *Enterococcus faecalis*. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++" represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S13a. Mass spectroscopy screening data for the dipeptide epimerase from Roseobacter litoralis Och 149. C-terminal specificity. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++" represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S13b. Mass spectroscopy screening data for the dipeptide epimerase from Roseobacter litoralis Och 149. N-terminal specificity. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++" represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S14. Mass spectroscopy screening data for the dipeptide epimerase from *Flavobacteria bacterium*  MS024-2A. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S15. Mass spectroscopy screening data for the dipeptide epimerase from *Populus trichocarpa.* Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S16. Mass spectroscopy screening data for the dipeptide epimerase from *Francisella tularensis*  subsp. novicida U112. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S17. Mass spectroscopy screening data for the dipeptide epimerase from *Flavobacterium johnsoniae* UW101. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.

	Gly- $L$ -Xxx	L-Ala- $L-Xxx$	$\operatorname{L-Thr}\nolimits$ $L-Xxx$	$L-Xxx-$ L-Ala	$\mbox{L-Xxx-}$ L-Ile	L-Xxx- L-Leu	$L-Xxx-$ L-Phe	$L-Xxx-$ $L-$ Arg/Lys	$L-Xxx-$ $L$ -Glu	L-Xxx- L-Asp
Gly										
Ala		$\boldsymbol{++}$			$\ddagger$		$\boldsymbol{++}$		$\boldsymbol{++}$	
Ser		$\boldsymbol{++}$								$\pmb{++}$
Pro										
Val				$\ddagger$					$\boldsymbol{+}$	
Thr		$\boldsymbol{++}$								
$\rm Leu/IIe$	$\boldsymbol{+}$	$\boldsymbol{++}$								
Asn										
Asp		$\boldsymbol{+}\boldsymbol{+}$								
Lys		$\boldsymbol{+}\boldsymbol{+}$								
Gln		$\boldsymbol{+}\boldsymbol{+}$								
Glu	$\boldsymbol{+}$	$\boldsymbol{+}$								
Met	$\boldsymbol{+}$	$\boldsymbol{++}$								
$\rm\thinspace His$		$\boldsymbol{++}$								
Phe		$\pmb{++}$								
Arg		$\boldsymbol{+}\boldsymbol{+}$								
Tyr		$\boldsymbol{++}$								$\boldsymbol{++}$
Trp		$\pmb{++}$								

Table S18. Mass spectroscopy screening data for the dipeptide epimerase from *Flavobacteriales bacterium* HTCC2170. Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S19. Mass spectroscopy screening data for the dipeptide epimerase from Bacteroides thetaiotaomicron. Deuterium incorporation was measured at 16 hours after incubation, unless otherwise specified. "+++" indicates >50% incorporation of deuterium, "++" represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium.



Table S20. Mass spectroscopy screening data for the dipeptide epimerase from *Cytophaga hutchinsonii.*  Deuterium incorporation was measured at 16 hours after incubation. "+++" indicates >50% incorporation of deuterium, "++"represents 25-50%, and "+" represents <25% incorporation. Blanks indicate no detectable incorporation of deuterium. "na" indicates that the specified dipeptide was not included in the screening.


	$k_{cat}$ [s <sup>-1</sup> ]	$K_M$ [mM]	$k_{cat}/K_M$ [M <sup>-1</sup> s <sup>-1</sup> ]
L-Ala-L-Glu	$147 \pm 10$	$2.0 \pm 1$	$7.4 \times 10^{4}$
L-Ala-D-Glu	$59 \pm 7$ $6.0 \pm 2$		$9.8 \times 10^{3}$
L-Val-L-Glu	$96 \pm 7$	$1.7 \pm 0.2$	5.6 $\times$ 10 <sup>4</sup>
L-Val-D-Glu	$43 \pm 6$	$4.4 \pm 2$	$9.8 \times 10^{3}$
L-Ile-L-Glu	$30 \pm 2$	$5.9 \pm 1$	5.1 $\times$ 10 <sup>3</sup>
L-Leu-L-Glu	٠	۰	$3.9 \times 10^{3}$
L-Pro-L-Glu	۰		$1.0 \times 10^{3}$

Table S21. Kinetic constants obtained for epimerization of dipeptide substrates for *Bacteroides thetaiotaomicron*.

	$k_{cat}$ [s <sup>-1</sup> ]	$K_M$ [mM]	$k_{cat}/K_M$ [M <sup>-1</sup> s <sup>-1</sup> ]
L-Ala-L-Ala	$37 \pm 3$ $5.0 \pm 0.7$		$7.5 \times 10^{3}$
L-Ala-L-Val	7.5	10	$7.5 \times 10^{2}$
L-Ala-L-Met	15	2.5	6.0 $\times$ 10 <sup>3</sup>
L-Ala-L-Leu	1.4	$1.4$	$1.0 \times 10^{3}$
L-Val-L-Ala	$5.5 \pm 0.05$	$9.9 \pm 0.3$	5.6 x $10^2$
L-Phe-L-Ala	$7.0 \pm 0.3$	$3.4 \pm 0.6$	$2.1 \times 10^{3}$
L-Leu-L-Ala	$21 \pm 0.8$	$22 \pm 2$	$9.4 \times 10^{2}$
L-Tyr-L-Ala	$3.0 \pm 0.1$	$3.6 \pm 0.6$	$8.3 \times 10^{2}$
D-Ala-D-Ala	$43 \pm 1.3$	$1.9 \pm 0.2$	$2.3 \times 10^{4}$
D-Ala-L-Ala	$58 \pm 4$	$1.1 \pm 0.3$	$5.3 \times 10^{4}$
D-Ala-L-Val	$19 \pm 0.8$ $0.50 \pm 0.1$		$3.7 \times 10^{4}$
D-Ala-L-Met	$15 \pm 0.9$	$2.5 \pm 0.4$	6.0 $\times$ 10 <sup>3</sup>
D-Ala-L-Leu	$5.0 \pm 0.2$		4.5 x $10^3$
D-Ala-L-Ser	68	6.2	1.1 $\times$ 10 <sup>4</sup>

Table S22. Kinetic constants obtained for epimerization of dipeptide substrates for *Cytophaga hutchinsonii*.



Table S23. Kinetic constants obtained for epimerization of dipeptide substrates for *Enterococcus faecalis*.



Table S24. Kinetic constants obtained for epimerization of dipeptide substrates for *Herpetosiphon aurantiacus*.



Table S25. Kinetic constants obtained for epimerization of dipeptide substrates for *Methylococcus capsulatus*.

	apo	L-Ile-L-Tyr	L-Leu-L-Tyr	L-Ser-L-Tyr	L-Arg-L-Tyr
Data collection					
Space group	R <sub>3</sub>	C2	R <sub>3</sub>	R <sub>3</sub>	R <sub>3</sub>
No. of mol. in asym. unit	$8\,$	$8\,$	$\,8\,$	$8\,$	$\,8\,$
Cell dimensions					
$a, b, c(\AA)$	162.3, 162.3, 319.6	194.9, 187.4, 91.9	163.9, 163.9, 318.7	163.7, 163.7, 318.1	163.3, 163.3, 317.6
$\beta$ (°)		90.01			
Resolution $(\AA)$	1.7	1.8	2.0	2.0	1.9
No. of unique reflections	341811	299981	205342	214313	245947
Rmerge	0.094	0.085	0.078	0.069	0.081
Completeness (%)	99.1	98.8	95.3	99.9	98.7
Refinement					
Resolution $(\AA)$	$25.0 - 1.7$	$25.0 - 1.8$	$25.0 - 2.0$	$25.0 - 2.0$	$25.0 - 1.9$
Rcryst	0.223	0.221	0.247	0.245	0.236
Rfree	0.224	0.254	0.281	0.282	0.270
No. atoms					
Protein	20920	20920	20920	20920	20920
Waters	888	1625	423	485	776
$Mg^{2+}$ ions	8	8	$\,8\,$	$8\,$	$\,8\,$
Bound ligand		L-Ile-L-Tyr	L-Leu-L-Tyr	L-Ser-L-Tyr	L-Arg-L-Tyr
Ligand atoms		168	168	152	192
R.m.s deviations					
Bond lengths (Å)	0.005	0.005	0.006	0.006	0.006
Bond angles (°)	1.2	1.1	1.1	$1.2$	1.2
PDB entry	3JVA	3JW7	3JZU	3K1G	3KUM

Table S26**.** Data collection and refinement statistics for the dipeptide epimerase from *E. faecalis*.

Table S27. Data collection and refinement statistics for the dipeptide epimerase from *B. thetaiotamicron*.



Table S28. Data collection and refinement statistics for the dipeptide epimerase from *C. hutchinsonii.*



	$Mg^{2+}$ -L-Arg-D-Lys	$\rm Mg^{2+}$	
<b>Data collection</b>			
Space group	$I2_13$	$P2_1$	
No. of mol. in asym. unit	5	6	
Cell dimensions			
$a, b, c (\AA)$	275.32, 274.32, 275.32	79.19 150.67 106.02	
$\alpha, \beta, \gamma$ (°)	90.00, 90.00, 90.00	90.00, 104.66, 90.00	
Resolution $(\AA)$	19.9-2.7 (2.80-2.70)	19.9-2.2 (2.24-2.20)	
No. of unique reflections	94445	121430	
$R$ merge	0.154(0.768)	0.144(0.541)	
$I/\sigma I$	12.85(2.03)	13.03(3.45)	
Completeness $(\% )$	99.8 (100.0)	99.8 (100.0)	
Refinement			
Resolution $(\AA)$	19.9-2.7	19.9-2.2	
Reryst	0.175	0.174	
$R$ free	0.222	0.229	
R.m.s. deviations			
Bond lengths $(A)$	0.008	0.008	
Bond angles (°)	1.339	1.264	
No. atoms			
Protein	13605	15936	
Waters	555	534	
Substrate	105		
$Mg2+ions$	5	6	
<b>B-factors</b>			
Wilson plot	52.4 25.1		
Protein	42.2 28.8		
Ligands	63.3	24.5	
Solvent	37.5	28.6	
PDB entry	3RIT	3RO6	

Table S29. Data collection and refinement statistics for the dipeptide epimerase from *M. capsulatus.*

**DATASET**<sup>a</sup>  $\left| \text{Tartrate, No Mg}^{2+} \right|$   $Mg^{2+} \left| \text{L-Ala, D/L-Glu,} \right|$ Space Group  $P_{41212}$  P4<sub>1212</sub> P41212 Unit Cell  $(A, ^{\circ})$   $a=b=121.0$ *c*=148.8 *a*=*b*=120.7 *c*=150.0  $a=b=121.2, c=149.0$ Resolution (Å)  $40-2.0$  (2.11-2.0)  $40-2.0$  (2.11-2.0) 30-1.9 (2.0-1.9) Completeness (%)  $100 (100)$  100 (100) 97.9 (92.5) Redundancy 28.8 (27.9) 27.8 (24.9) 12.5 (12.1) Mean(I)/sd(I) 27.6 (11.9) 22.2 (8.1) 16.4 (5.8) Rsym 10.093 (0.312) 0.122 (0.430) 0.097 (0.380) Wilson B Factor  $(Å2)$ 19.4 18.1 18.3 **REFINEMENT** Resolution (Å)  $40-2.0$  (2.02-2.0)  $40-2.0$  (2.07-2.0) 40-1.9 (1.97-1.9) Unique reflections  $(2706)$   $(74276 (2706)$   $(74571 (7301)$   $(84359 (7647))$ Rcryst (%) 16.5 (16.1) 16.0 (16.7) 15.7 (18.2) Rfree (%, 5% of data) 19.7 (19.8) 19.1 (21.2) 18.5 (21.6) **Contents of model** Residues  $(1-356)^b$  A2-22, A30-A363, B2-B365 A2-363, B2- 365 A2-363, B2-365 Waters 1 559 578 708  ${ {\rm Mg}^{2+}}$  0 1 0 Other 1 59 77 83 Atoms total 6172 6260 6404 **Average B-factor (Å<sup>2</sup> )** Protein/Waters/Ligand  $27.3 / 35.4 / 55.3$  19.0 / 28.9 / - 23.2 / 34.0 / 23.0

Table S30. Data collection and refinement statistics for the dipeptide epimerase from *F. philomiragia*



*a* Statistics in parenthesis are for the highest resolution bin

*b* Additional residues past 356 are from C-terminal tag

*<sup>c</sup>* Scores are ranked according to structures of similar resolution as formulated in **MOLPROBITY** 

Data collection	
Space group	P <sub>21</sub>
Cell dimensions	
a, b, c(A)	84.026, 93.344, 85.914
$\alpha, \beta, \gamma$ (°)	90.00, 112.60, 90.00
Resolution $(\AA)$	$2.07 - 50.00(2.07 - 2.14)$ *
Rmerge	0.063(0.78)
$I/\sigma I$	7.9(0.9)
Completeness (%)	98.9(91.2)
Refinement	
Resolution	2.1
No. reflections	68809
$R_{\text{work}}$ / $R_{\text{free}}$	0.217/0.275
No. atoms	
Protein	10290
Ligand/ion	4
Water	249
$B$ -factors	
Protein atoms	42.09
Solvent atoms	34.76
R.m.s. deviations	
Bond lengths $(A)$	0.009
Bond angles $(°)$	1.25
Ramachandran Plot Statistics	
Most favored regions	90.20%
Additional allowed regions	9.00%
Generously allowed regions	0.70%
PDB entry	3IK4

Table S31. Data collection and refinement statistics for the dipeptide epimerase from *H. aurantiacus*

\*Values in parentheses are for highest-resolution shell.

#### **SUPPLEMENTARY METHODS**

#### **Detailed Methods: General**

Restriction enzymes, Platinum Pfx DNA polymerase, and T4 DNA ligase were purchased from Invitrogen. Some restriction enzymes were purchased from New England Biolabs Inc. Commercially available dipeptides were purchased from Bachem America, Inc., Sigma/Aldrich, Chem-Impex International, or INDOFINE Chemical Company. Reagents for dipeptide synthesis were purchased from EMD Biosciences or Sigma/Aldrich. Oligonucleotide primers were synthesized by Bio-Synthesis Inc. (Lewisville, TX). Crystallization screens were purchased from Hampton Research. All other reagents were purchased from Sigma/Aldrich or Fisher and were of the highest quality grade available.

All <sup>1</sup>H NMR spectra were recorded on a Varian Unity INOVA 500NB MHz spectrometer. Electrospray ionization (ESI) mass spectrometry spectra were acquired on a quadrupole-hexapole-quadrupole (QHQ) mass spectrometer (Quattro II) from Waters using MassLynx software.

#### **Detailed Methods: Solution phase synthesis of dipeptide substrates**

*Dipeptide Libraries.* Syntheses of dipeptide libraries were performed by the solid phase peptide synthesis methods described by Song *et al.* (1)

*Synthetic Dipeptides.* D-Ala-L-Val, D-Ala-L-Ile, D-Ala-L-Met, D-Ala-L-Leu, L-Ala-D-Glu, L-Val-L-Glu, and L-Val-D-Glu were synthesized by solution phase methods. The synthetic procedures and characterization are described below.

#### *Synthesis of D-Ala-L-Val*

A typical reaction mixture for the synthesis of D-Ala-L-Val was set up in 14 mL of CHCl3 and contained 2 mmoles of Boc-D-Ala-OH and H-Val-OMe. For coupling, 4 mmoles of 1-hydroxybeonzotriazole (HOBt) and N,N'-diisopropylcarbodiimide were added and placed on a shaker for overnight incubation at room temperature (RT). The mixture was filtered and rotary evaporated to a syrup and washed 3 times with chilled acetone; the white precipitate was filtered and discarded. Remaining pale yellow solution was applied to a silica column (2 cm x 30 cm) and eluted with 125 mL of acetone. Fractions were spotted on a TLC and visualized for the presence of Boc-D-Ala-L-Val-OMe with ninhydrin spray. Fractions containing the protected dipeptide were rotary evaporated to a syrupy substance. The protective groups were removed in two steps: incubation with 1:1 mix of 2 N NaOH and CH<sub>3</sub>OH for 2 hours at RT, rotaryevaporation to syrup, incubation with 2:1 mix of TFA and  $CH_2Cl_2$  for 2 hours at RT, and rotaryevaporated to syrup. Five mL of ddH<sub>2</sub>O was added to the syrup and washed 3 times with ethyl ether until the organic layer turned colorless. In some cases when further purification was necessary, the dipeptide concentrate was acidified to pH  $\sim$ 2 and applied to a Dowex 50W-X2 cation exchange column (Sigma) in the H<sup>+</sup> form (1.6 cm x 50 cm) and eluted with 1000 mL with a linear gradient of 0-0.5M HCl. The fractions were spotted on a TLC and visualized with ninhydrin spray (Sigma). The purity of the dipeptide was determined by  ${}^{1}H$  NMR.  ${}^{1}H$  NMR (D<sub>2</sub>O) for D-Ala-L-Val:  $\delta$  0.75 [6H, dd,  $J = 6.9$  and 16, -CH(CH<sub>3</sub>)<sub>2</sub>], 1.35 (3H, d,  $J = 7.1$ , -CH<sub>3</sub>), 2.0 [1H, m, -C*H*(CH3)2], 3.9 (1H, q, *J* = 7.2, 7.0 and 21.3, -C*H*(CH3)-], 3.93 {1H, d, *J* = 5.6, -  $CH[CH(GH<sub>3</sub>)<sub>2</sub>]$ -} (Figure A).



**Figure** A. <sup>1</sup>H NMR spectrum of D-Ala-L-Val at pD  $\sim$ 8.0.

## *Synthesis of D-Ala-L-Ile*

The synthesis of D-Ala-L-Ile was carried out as described for D-Ala-L-Val. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for D-Ala-L-Ile:  $\delta$  0.71 (3H, t,  $J = 7.4$ ) and 14.9,  $-CH_2CH_3$ ), 0.74 [3H, d,  $J = 6.9$ ,  $-CH(CH_3)CH_2CH_3$ ], 1.00 and 1.23 (2H, m,  $-CH_2CH_3$ ), 1.32 (3H, d, *J* = 7.1, -CH3), 1.72 [1H, m, -C*H*(CH3)CH2CH3], 3.88 [1H, q, *J* = 7, 7.1 and 21.2, - C*H*(CH<sub>3</sub>)-], 3.94 {1H, d,  $J = 5.9$ , -C*H* [CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>]-} (Figure B).



*Figure B.* <sup>*l*</sup> *H NMR* spectrum of *D-Ala-L-Ile at pD ~8.0.* 

*Synthesis of D-Ala-L-Met*

The synthesis of D-Ala-L-Met was carried out as described above. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for D-Ala-L-Met:  $\delta$  1.32 (3H, d,  $J = 7.1$ , -CH3), 1.80 and 1.96 (2H, m, -C*H*2CH2SCH3), 1.94 (3H, s, -SCH3), 2.35 and 2.43 (2H, m, - CH<sub>2</sub>CH<sub>2</sub>SCH<sub>3</sub>), 3.85 [1H, q,  $J = 7.1$ , 7.1 and 21.2, -CH(CH<sub>3</sub>)-], 4.14 [1H, q,  $J = 4.4$ , 5 and 13.8, - $CH(CH_2CH_2SCH_3)$ -] (Figure C).



**Figure C**. <sup>1</sup>H NMR spectrum of D-Ala-L-Met at pD  $\sim$ 8.0.

## *Synthesis of D-Ala-L-Leu*

Synthesis of D-Ala-L-Leu was carried out as described earlier. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for D-Ala-L-Leu:  $\delta$  0.75 [6H, dd,  $J = 6.3$ and 20.2, -CH(*CH3*)2], 1.29 (3H, d, *J* = 7.1, -*CH3*), 1.46 [3H, m, -*CH2CH*(CH3)2], 3.78 [1H, q, *J*  $= 7.1, 7.1$  and 21.2,  $\text{-}CH(CH_3)$ -], 4.03 {1H, t,  $J = 5.7, 8.7$  and 14.5,  $\text{-}CH[CH_2CH(CH_3)_2]$ -} (Figure D).



*Figure D.* <sup>*I*</sup>H NMR spectrum of D-Ala-L-Leu at pD ~7.0.

## *Synthesis of L-Ala-D-Glu*

The synthesis of L-Ala-D-Glu was carried out as described above, with the exception of the last purification step. The pH of the dipeptide was adjusted to  $\sim$ 12 with NH<sub>4</sub>OH and then applied to a Dowex AG1-X8 anion exchange column in the acetate form. The column was subsequently washed with ddH<sub>2</sub>O. The dipeptide substrate was typically eluted with a 1000 mL with a gradient of 0-1M acetic acid. The same purification procedure was used for all glutamate containing dipeptides.. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for D-Ala-L-Glu: ! 1.33 (3H, d, *J* = 7, -CH3), 1.72 and 1.92 (2H, m, -*CH2*CH2CO2H), 2.06 (2H, t,  $J = 8.1$  and 16.1, -CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H), 3.84 [1H, q,  $J = 7.1$ , 7.1 and 21.3, -CH(CH<sub>3</sub>)-], 3.96 [1H, q,  $J = 4.2$ , 5.1 and 13.7,  $-CH(CH_2CH_2CO_2H)$ -] (Figure E).



*Figure E.* <sup>*H*</sup> *NMR of L-Ala-D-Glu at pD ~8.0.* 

## *Synthesis of L-Val-L-Glu*

The synthesis of L-Val-L-Glu was carried out as described for L-Ala-D-Glu. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for L-Val-L-Glu:  $\delta$  0.79 [6H, dd, *J* = 6.9 and 18.5, -CH(C*H*3)2], 1.83 [3H, m, -*CH*(CH3)2, -*CH2*CH2CO2H], 2.08 [2H, t, *J* = 8.4 and 17, -CH2*CH2*CO2H] , 3.08 {1H, d, *J* = 6.1, -*CH*[CH(CH3)2]-}, 4.2 [1H, q, *J* = 4.6, 4 and 13.4, -  $CH(CH_2CH_2CO_2H)$ -] (Figure F).



*Figure F.* <sup>*I*</sup>H NMR spectrum of L-Val-L-Glu at pD ~8.0.

*Synthesis of L-Val-D-Glu*

The synthesis of L-Val-D-Glu was carried out as described for L-Ala-D-Glu. The purity of the dipeptide was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (D<sub>2</sub>O) for D-Val-D-Glu:  $\delta$  0.85 [6H, dd, *J*  $= 2$  and 6.8,  $\text{-CH}(CH_3)_2$ ], 1.74 and 1.94 [3H, m,  $\text{-CH}(CH_3)_2$ ,  $\text{-CH}_2CH_2CO_2H$ ], 2.08 [2H, t,  $J = 8$ ] and 17.1,  $-CH_2CH_2CO_2H$ ], 3.47 {1H, d,  $J = 6.6$ ,  $-CH[CH(CH_3)_2]$ }, 3.98 [1H, q,  $J = 4.3$ , 5.1 and 13.7, *-CH*(CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H)-] (Figure G).



*Figure G.* <sup>*I*</sup>H NMR spectrum of L-Val-D-Glu at pD ~7.0.

## **L-Arg-L-Lys synthesis**

C-terminal amino acid with a protecting group t-butyl ester (OtBu), 1 mmol of H-Lys(Boc)-OtBu HCl, was dissolved in 10 mL of dry DMF solvent. Then, 270 mg of HOBT (2) molar equivalent), and 722 uL of DIC (4 molar equivalent) were added to the solution, followed by addition of N-terminal amino acid protected by Boc, 1 mmol of Boc-Arg $(Boc)_{2}$ -OH. After combining all, the coupling reaction proceeded with shaking at room temperature for 16 hr and the dipeptide production was monitored by TLC. The reaction mixture was filtered to remove the precipitated residues and concentrated to a syrup using a high-vac rotary evaporator over a 30 °C bath. The syrup was washed with acetone solution three times. The crude dipeptide product was purified by silica gel chromatography to remove the unreacted starting materials. The purified product from silica gel chromatography was concentrated to a crude dipeptide product

with protecting groups which was dissolved in 9 mL of  $TFA/CH_2Cl_2$  (1:2 mixture) to remove protecting groups, OtBu and Boc. The reaction proceeded with stirring at room temperature for 2 hr. Then the solvent was removed using a high-vac rotary evaporator over a 40 °C bath. The product was dissolved in 10 mL ddH2O and impurities were removed by 10 mL ethyl ether extraction which was repeated three times. The product was then purified over Dowex AG-50 cation exchange resin, eluting with  $0 - 3$  N HCl. Fractions containing pure dipeptide were identified by TLC, combined, and concentrated using a high-vac rotary evaporator over a 40 °C bath. 5 mL ddH<sub>2</sub>O was added to the concentrated dipeptide product, and the pH was adjusted to  $6 - 8$ . The water was removed to obtain the final dried product by lyophilization. The product yield was 114 mg (28% yield) and characterized by <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): 4.06 ppm (1H, m, HO<sub>2</sub>CCHNH), 3.94 ppm (1H, m, NH<sub>2</sub>CHCOO), 3.12 ppm (2H, t, J = 7.5 Hz,  $CH_2CH_2CH_2NH$ ), 2.89 ppm (2H, t, J = 7.9 Hz,  $CH_2CH_2CH_2CH_2NH_2$ ), 1.86 – 1.30 ppm (4H, m,  $CH_2CH_2CH_2NH$ , and  $1.86 - 1.30$  ppm (6H, m,  $CH_2CH_2CH_2CH_2NH_2$ ).



*Figure H.*  ${}^{1}$ H NMR spectrum of L-Arg-L-Lys.

## **L-Arg-L-Orn synthesis**

L-Arg-L-Orn substrate synthesis was performed following the protocol described in the previous section except the next two points. First, protected C-terminal amino acid with methyl ester (OMe), 1 mmol of H-Orn(Boc)-OMe HCl, was added to the reaction instead of H-

Lys(Boc)-OtBu·HCl. Second, an extra deprotection reaction was performed to remove OMe before the deprotection reaction by  $TFA/CH_2Cl_2$ . After silica gel chromatography separation, 10 mL of MeOH/NaOH (2 N) (1:1 mixture) was added to the crude product and stirred at room temperature for 2 hr. The product yield was 119 mg (41% yield) and characterized by <sup>1</sup>H NMR  $(500 \text{ MHz}, D_2O)$ : 4.09 ppm (1H, m, HO<sub>2</sub>CCHNH), 3.94 ppm (1H, m, NH<sub>2</sub>CHCOO), 3.11 ppm  $(2H, t, J = 7.4 \text{ Hz}, CH_2CH_2CH_2NH)$ , 2.91 ppm  $(2H, t, J = 7.2 \text{ Hz}, CH_2CH_2CH_2NH_2)$ , 1.86 – 1.51 ppm (4H, m,  $CH_2CH_2CH_2NH$ ), and  $1.86 - 1.51$  ppm (4H, m,  $CH_2CH_2CH_2NH_2$ ).



*Figure I*. <sup>1</sup>H NMR spectrum of L-Arg-L-Orn.

## **L-Arg-L-Ser synthesis**

L-Arg-L-Ser substrate synthesis was performed following the protocol described in the section of L-Arg-L-Lys synthesis except that protected C-terminal amino acid, 0.5 mmol of H-Ser(tBu)-OtBu HCl with *tert*-butyl (tBu) protecting group, was added to the reaction instead of H-Lys(Boc)-OtBu HCl and that the amount of chemical used was reduced to half. The product yield was 111 mg (85% yield) and characterized by <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): 4.22 ppm (1H, m, HO<sub>2</sub>CCHNH), 3.97 ppm (1H, m, NH<sub>2</sub>CHCOO), 3.76 ppm (2H, m, CHCH<sub>2</sub>OH), 3.13 ppm (2H, t, J = 6.8 Hz, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH), 1.86 ppm (2H, m, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 1.60 ppm (2H, m,  $CH_2CH_2CH_2NH_2$ ).



Figure J. <sup>1</sup>H NMR spectrum of L-Arg-L-Ser.

## **L-Orn-L-Arg synthesis**

L-Orn-L-Arg substrate synthesis was performed following the protocol described in the section of L-Arg-L-Lys synthesis except the two starting materials; Boc-Orn(Boc)-OH for the Nterminal amino acid and H-Arg-(OtBu) 2HCl for the C-terminal amino acid. Two deprotection steps, first with MeOH/NaOH and second with  $TFA/CH_2Cl_2$ , were performed during purification. The product yield was 151 mg (38% yield) and characterized by  ${}^{1}H$  NMR (500 MHz, D<sub>2</sub>O): 4.08 ppm (1H, m, HO<sub>2</sub>CCHNH), 3.95 ppm (1H, m, NH<sub>2</sub>CHCOO), 3.13 ppm (2H, t,  $J = 6.9$  Hz, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH), 2.93 ppm (2H, t,  $J = 7.4$  Hz, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 1.87 – 1.51 ppm (4H, m,  $CH_2CH_2CH_2NH_2$ ), and 1.87 – 1.51 ppm (4H, m,  $CH_2CH_2CH_2NH$ ).



*Figure K*. <sup>1</sup>H NMR spectrum of L-Orn-L-Arg.

#### **L-Val-L-Arg synthesis**

L-Val-L-Arg substrate synthesis was performed following the protocol described in the section of L-Arg-L-Lys synthesis except the two starting materials; Boc-Val-OH for the Nterminal acid and H-Arg(OtBu) 2HCl for the C-terminal amino acid. The product yield was 24.0 mg (8.8% yeild) and characterized by <sup>1</sup>H NMR (500MHz, <sup>2</sup>H<sub>2</sub>O); 4.22 ppm (1H, m,  $HO_2CCHNH$ ), 3.48 ppm (1H, m, NH<sub>2</sub>CHCOO), 3.01 ppm (2H, m, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH), 2.15 ppm (1H, m, CHCH<sub>3</sub>CH<sub>3</sub>), 1.18 ppm (4H, m, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), and 0.918 ppm (6H, m,  $CHCH<sub>3</sub>CH<sub>3</sub>$ ).



Figure L. <sup>1</sup>H NMR spectrum of L-Val-L-Arg.

#### **Detailed Methods: Cloning, Expression and Purification**

*Cloning, Expression, and Purification of the Dipeptide Epimerase from Bacteroides thetaiotaomicron VPI-5482 ATCC 29148 (GI: 29346723).* Alignment of the sequence of BT1313 with those of other dipeptide epimerases suggested that the N-terminal Met for BT1313 is Met 46 in the GenBank sequence. Therefore, the gene BT1313 was PCR-amplified from genomic DNA using primers that amplified the coding sequence for residues 46 383 in the GenBank sequence: 5' CATATTAATAAATATGGTATA-GGGGGACATATGAAAATGACTTTTTTCCC-3' and 5' cattctcgaggatcagattttcatgacaccaatccgggtaagtc-3', containing 5' *Nde*I and 3' *Xho*I restriction sites (underlined), respectively. The PCR reaction mixture (100  $\mu$ L) contained 0.5  $\mu$ L of 100 ng/mL template DNA, 2 µL of 50 mM MgSO4, 0.5 µL of 2.5 units/µL platinum *Pfx* DNA polymerase, 10  $\mu$ L of 10× *Pfx* amplification buffer, 10  $\mu$ L of 10× enhancer buffer, 2  $\mu$ L of 20 mM dNTP mix, 2  $\mu$ L of each 20  $\mu$ M forward and reverse primer, and 71  $\mu$ L of ddH<sub>2</sub>O. The PCR was performed with the following program: 94 °C for 3 min followed by 40 cycles of 94 °C for 1 min, 65 °C for 1.25 min, 68 °C for 3 min, and a final extension at 68 °C for 10 min. The product was purified using a Qiagen gel extraction kit (Qiagen, Inc). The product was then digested with *NdeI* and *XhoI* for 2 hr at 37 °C and gel purified. The digested product was ligated overnight with T4 DNA ligase into the pET 17b expression vector (Novagen) that had been digested with *Nde*I and *Xho*I. The sequence of the gene was verified at the University of Illinois Core Sequencing Facility.

The gene of interest was expressed using the pTara expression system in *E. coli* MG1655 in which the chromosomal gene encoding L-Ala-D/L-Glu epimerase had been disrupted. For a typical protein purification batch, the cells were grown in 4 L of LB medium in the presence of 34  $\mu$ g/mL of chloramphenicol and 100  $\mu$ g/mL of ampicillin at 25°C for 3 days and harvested by centrifugation. The cells were suspended in 20 mM Tris-Cl, pH 8.0, containing 5 mM  $MgCl<sub>2</sub>$  and lysed on ice using Fisher Scientific 550 Sonic Dismembrator. The insoluble cell debris was removed by centrifugation. The supernatant was applied to a DEAE-Sepharose FF column (2.5 cm  $\times$  50 cm, GE Healthcare) and eluted with a linear gradient (1600 mL) of 0 to 1 M NaCl buffered with 20 mM TrisCl, pH 8.0, and 5 mM  $MgCl<sub>2</sub>$ . Fractions containing the protein were applied to Phenyl Sepharose 6FF (low sub) column (1.6 x 20 cm, GE Healthcare) in 0.5 M  $(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>$  and 20 mM Tris-Cl, pH 7.9, for further purification. The column was washed with 100 mL of 0.5 M (NH4)2SO4 in 20 mM Tris-Cl, pH 7.9 and eluted with a linear gradient of 0.5 to

0 M ( $NH_4$ )<sub>2</sub>SO<sub>4</sub> (600 mL) containing 20 mM Tris -Cl, pH 7.9, and 5 mM MgCl<sub>2</sub>. The protein was then dialyzed against 50 mM Tris-Cl, pH 7.9, containing 100 mM NaCl and 5 mM  $MgCl<sub>2</sub>$ for storage. The protein was subjected to ESI-MS to confirm the correct molecular weight (expected mass of 37,493.4 Da, observed mass of 37,495.0 Da). The protein was determined to be a monmer by HPLC size exclusion chromatography.

*Cloning, Expression, and Purification of the Dipeptide Epimerase from Cytophaga hutchinsonnii ATCC 33406 (GI:110638536)*. The gene encoding the putative dipeptide epimerase was PCR amplfied from genomic DNA using the primers 5' gtctttttttcgtataggtgtattaatatgattataacacagg-3' and 5'-cacaaactcgaggcgctcagtttat-gcatattttttc-3', containing 5' *Ase*I and 3' *Xho*I restriction sites (underlined), respectively. The procedure described in the previous section was used for PCR amplificiation, purification, digestion (with *Ase*I and XhoI), and ligation of the PCR product into the pET-17b expression vector.

For a typical protein purification, the cells in BL21 were grown in 4L of LB medium at 25 °C for 3 days in the presence of 100  $\mu$ g/ $\mu$ L of ampicillin. The cells were harvested by centrifugation and resuspended in 60 mL of 20 mM Na<sup>+</sup>-HEPES, pH 8.35, containing 5 mM MgCl<sub>2</sub>. The suspension was then lysed on ice using a Fisher Scientific 550 Sonic Dismembrator; the cell lysate was centrifuged to remove insoluble debris. The supernatant was applied to a DEAE-Sepharose FF column and eluted with a linear gradient (1600 mL) of 0 to 0.5 M NaCl buffered with 20 mM Na<sup>+</sup>-HEPES, pH 8.35, containing 5 mM MgCl<sub>2</sub>. For crystallization purposes, further purification of the protein was halted at this point. Fractions containing the protein, as determined by SDS-PAGE were pooled and glycerol was added to a final concentration of 10%. For enzymatic assays, fractions containing the protein were applied to

Phenyl Sepharose 6FF column (1.6 x 20 cm, GE Healthcare) in 0.5 M ( $NH<sub>4</sub>$ )<sub>2</sub>SO<sub>4</sub> and 20 mM Na<sup>+</sup>-HEPES, pH 7.9, for further purification. The column was washed with 100 mL of 0.5 M  $(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>$  in 20 mM Na<sup>+</sup>-HEPES, pH 7.9 and eluted with a linear gradient of 0.5 to 0 M  $(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>$  (600 mL) containing 20 mM Na<sup>+</sup>-HEPES, pH 7.9, and 5 mM MgCl<sub>2</sub>. The protein was dialyzed against 50 mM Na<sup>+</sup>-HEPES, pH 7.9, containing 100 mM NaCl and 5 mM MgCl<sub>2</sub> for storage. The protein was subjected to ESI-MS to confirm the correct molecular weight (expected mass of 40,310.6, observed mass of 40,313.0). The protein was determined to be a monomer by HPLC size exclusion chromatography.

*Cloning, Expression and Purification of the Dipeptide Epimerase from Enterococcus faecalis (GI:29376078)*. The gene encoding the putative dipeptide epimerase was cloned from *E. faecalisi* genomic DNA using *Taq* DNA polymerase and primers that specified an *Nde* I recognition site at the 5' end end and a *Bam* HI recognition site at the 3' end of the gene. Following purification by gel electrophoresis, the amplified PCR product was restricted using *Nde* I and *Bam* HI restriction enzymes per the manufacturer's protocols. The gene was then ligated into pET17b using T4 DNA ligase and transformed in *E. coli* XL1Blue cells for plasmid amplification and maintenance.

For large scale purification, 2L of LB containing 100 µg/mL ampicillin was inoculated with 5 mL of a starter culture of BL21 cells transformed with the pET17b derived plasmid. The culture was grown at 37°C without induction by IPTG for 24 hours and then harvested by centrifugation. The cell pellet was resuspended in 60 mL of cold low salt buffer (10 mM Tris - Cl, pH 7.9, containing 5 mM  $MgCl<sub>2</sub>$  and lysed by sonication. The lysate was cleared by centrifugation, and the supernatant was loaded onto a DEAE Sepharose Fast Flow column. The protein was eluted with a linear gradient (1600 mL) of 0 to 1 M NaCl buffered with 10 mM Tris HCl, pH 7.9, containing 5 mM  $MgCl<sub>2</sub>$ . The fractions containing the purest protein as assessed by SDS PAGE were pooled. The protein containing solution was dialyzed three times against low salt buffer at 4<sup>o</sup>C and then loaded onto Q Sepharose HP column (1.7 x 7 cm, GE Healthcare). The protein was eluted with a linear gradient (250 mL) of 0 to 1 M NaCl in 10 mM Tris-HCl, pH 7.9, containing 5 mM MgCl<sub>2</sub>. Fractions containing pure protein were dialyzed three times at  $4^{\circ}$ C against 20 mM Tris-HCl, pH 7.9, containing 100 mM NaCl and 5 mM  $MgCl<sub>2</sub>$ . The solution was concentrated to  $\sim$ 10 mg/mL for assays and  $\sim$ 45 mg/mL for crystallization.

*Cloning, Expression, and Purification of the Dipeptide Epimerase from Methylococcus capsulatus str. Bath (GI: 53757661).* The gene encoding the dipeptide epimerase (GI: 53757661) was amplified by PCR from *Methylococcus capsulatus str. Bath* genomic DNA (kindly provided by Prof Live J. Bruseth at University of Bergen, Norway) using the following primers: 5' GGAACGGGAGGAAGTCATATGAAGATCGCCGACATC 3' and 5' GGAATTGCATCGGGGATCCTCTAATCCGGGTATACG 3' containing a 5' *Nde*I site and a 3' *Bam*HI site (underlined), respectively. PCR reactions in 50 µL total volume contained 100 ng template, 1 mM MgSO4, 2.5 U of platinum *Pfx* DNA polymerase, 2X *Pfx* amplification buffer, 2X enhancer buffer, 0.4 mM of each dNTP, and 0.4 µM of each forward and reverse primer. The PCR reaction was performed with the following parameters: 94° C for 5 min followed by 40 cycles of 94° C for 1 min, 60° C for 1.25 min, and 68° C for 3 min; the final extension time was 10 minutes at 68° C. Following purification by gel extraction, the amplified PCR product was restricted using *Nde*I and *Bam*HI restriction enzymes per the manufacturer's protocols. The gene was then ligated into the non-tagged expression vector pET17b using T4 DNA ligase and transformed in *E. coli* XL1Blue cells for plasmid maintenance.

The cloned dipeptide epimerase from *M. capsulatus* was expressed in *E. coli* BL21 (DE3) cells for protein purification. In a typical protein preparation, 2 L of LB media was shaken at 37°C without induction and harvested after 48 hours by centrifugation. The cells were resuspended in 80 mL of buffer containing 20 mM Tris-HCl, pH 8.0, and 5 mM  $MgCl<sub>2</sub>$ . The suspension was lysed by sonication and debris was cleared by centrifugation. The supernatant was applied to a DEAE Sepharose FF column and eluted with a linear gradient (1600 mL) of 0 to 1 M NaCl buffered with 20 mM Tris HCl, pH 8.0, containing 5 mM  $MgCl<sub>2</sub>$ . Fractions containing the protein of interest were pooled and applied to a Phenyl Sepharose 6 Fast Flow column in 0.6 M ( $NH_4$ )<sub>2</sub>SO<sub>4</sub> for further purification. The protein was eluted with a linear gradient (800 mL) of 0.6 to 0 M ( $NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>$  and the purest fractions were pooled and dialyzed against 20 mM Tris-HCl, pH 8.0 and 5 mM  $MgCl<sub>2</sub>$ . For crystallization purposes, the protein was subjected to an additional size exclusion chromatography step to enhance homogeneity. Five mL of the enzyme was applied onto a HiLoad 16/60 Superdex 75 pg column (16 mm X 60 cm, GE Healthcare) and eluted with 50 mM K<sup>+</sup>-HEPES, pH 8.0, containing 5 mM  $MgCl<sub>2</sub>$ , and 100 mM KCl. The protein was concentrated to 10 - 15 mg/mL using a Millipore Amicon apparatus fitted with a 10,000 NMWL ultrafiltration membrane and stored at 4°C.

# *Cloning, Expression, and Purification of the Dipeptide Epimerase from Francisella philomiragia ATCC 25017 (GI:167627873, NYSGRC-200555)*.

The gene for EFI target 200555 was produced using codon optimized whole gene synthesis and cloned into a modified pET30 vector utilizing ligation independent cloning and primers 5' TTAAGAAGGAGATATACCATGGTGTCAAAAATCATCGACATCAAGACCC 3'

5' gattggaagtagaggttctctgcCAGATTAAAACCAAACCCCTTCAG 3' as PCR primers. The modified pet30 vector produces protein with a C-terminal TEV cleavable duel hexahis-STREP tag (sequence CTERM-AENLYFQSHHHHHHWSHPQFEK). Protein was expressed in BL21(DE3)T1R-RIL in a LEX48 (Harbinger Biotechnology) fermentor. 10 ml of an overnight culture was added to a 1L bottle containing M9 SeMET High-Yeild Growth Media (Shanghai Medicilon Inc.) with 100  $\mu$ g/L SeMET and 100  $\mu$ g/ml Kanamyacin. Cells were grown at 38.5 °C to an OD600 of 1.2. The temperature of the culture was reduced to 20 °C whereupon IPTG was added to 1mM. Cells were grown for 12-16 hours after which they were pelleted by centrifugation at 4000g for 15 minutes.

Pellets were resuspended in 25 mls of buffer A (20mM HEPES pH 7.6, 300 mM NaCl, 10% glyerol, 0.1% Sodium Azide) containing 1 mM PMSF and 1 ug/ml DNase and lysed by sonication. Cells were pelleted at 6000 g for 45 minutes. The supernatent was applied to a Strep-Tactin (IBA) column, washed with 5 column volumes of buffer A, and eluted with buffer B (20 mM HEPES, pH = 7.6, 300 mM NaCl, 2.5 mM Desthiobiotin, 10% Glycerol, 0.1% Sodium Azide) directly onto a 1ml HighTrap Fast Flow Ni-NTA column (GE-Healthcare). The bound protein was washed with 10 column volumes of buffer C (20 mM HEPES, pH 7.5, 500 mM NaCl, 20 mM Imidazole, 10% Glycerol, 0.1% Sodium Azide) prior to being eluted from the column with buffer D (20 mM HEPES, pH 7.5, 500 mM NaCl, 500 mM Imidazole, 10% Glycerol, 0.1% Sodium Azide), with the peak fraction captured and loaded onto a HighFlow Superdex S200 16 60 Prep Grade column (GE-Helathcare) equilbrated with buffer E ( 20 mM HEPES, pH = 7.5, 150 mM NaCl, 10% Glycerol, 0.1% Sodium Azide, 0.5mM TCEP). Peak fractions eluting at the correct volume for the expected mass were pooled and concentrated to 10-15 mg using centrifugal concentrators.

#### **Detailed Methods: Screening by Mass Spectroscopy**

Typical assay conditions for the incubation of dipeptide epimerases with dipeptide libraries are as follows: Screens were carried out in  $D_2O$  (50-250  $\mu$ L) containing 20 mM  $NH<sub>4</sub>HCO<sub>3</sub>$  (pD 7.9) and between 100  $\mu$ M and 1 mM of each dipeptide. A portion of the solution was set aside as a negative control; the dipeptide epimerase was added to the remaining solution at a concentration of 1  $\mu$ M. The reactions were incubated at 37 °C and quenched at various time intervals (from 30 min to 16 hr), quenched with 2  $\mu$ L 5M NH<sub>4</sub>OH, and dried by Speedvac. The sample was resuspended in 25  $\mu$ L of ddH<sub>2</sub>O and diluted 1:1 with methanol. Analysis for incorporation of solvent deuterium was carried out by ESI mass spectrometry where a M+1 mass shift indicates deuterium incorporation. The analysis was carried out in positive mode for all libraries with a net neutral or positive charge; the negative mode was used for libraries with a net negative charge. In some cases, the screening was repeated with lower concentrations of enzyme and with shorter incubation times to better assess substrate specificity.

#### **Detailed Methods: Kinetics**

Kinetic parameters were determined via polarimetry. The difference in optical rotation between the initial reading before enzyme was added and after attainment of equilibrium was used to obtain the value for the change in molar ellipticity. The assays were carried out in a 100 mm pathlength cuvette and a Jasco P-1010 polarimeter and a Hg 405 nm filter. Assays were performed at room temperature ( $\sim$ 28°C) in a total volume of  $\sim$ 1.4 mL. Typical buffer conditions for the assay were the following: 20 mM Tris-HCl (pH 8.0) and 10 mM MgCl<sub>2</sub>. Values for  $k_{cat}$ and  $K_M$  were determined by fitting initial velocities to the Michaelis-Menten equation using

EnzFitter (Biosoft, Cambridge, UK), and subsequent rate constants were divided by two to account for reversibility as the  $K_{eq}$  values were  $\sim$ 1. A minimum of two independent sets of kinetic analysis were used to determine standard deviations.

#### **Detailed Methods: Computation**

*Network Analysis.* BLAST e-values for sequences in the dipeptide epimerase family were obtained from the Structure Function Linkage Database (SFLD).(2) SFLD BLAST searches are performed by comparing each sequence in a superfamily against each other. For efficiency, searches are performed by BLASTing bundles of 100 query sequences against all other superfamily sequences. Results are post processed to obtain the equivalent blast2seq evalue (independent of database size) based on bit score. Cytoscape networks (3) were created from these BLAST results at several different e-value cutoffs. Tools used for visualization of protein networks were created by the UCSF Resource for Biocomputing, Visualization, and Informatics and are available from the Resource (http://www.rbvi.ucsf.edu). Each node in the network represents a single sequence in the dipeptide epimerase family and each edge represents the pairwise connection between two sequences with the most significant BLAST e-value (better than the cut-off) connecting the two sequences. The nodes were arranged using the yFiles organic layout provided with Cytoscape version 2.7. Using this layout, lengths of edges are not meaningful except that sequences in tightly clustered groups are relatively more similar to each other than sequences with few connections. Annotation information, including species, lineage, and available x-ray structures (obtained from the SFLD) and substrate specificity (obtained from this study) was associated with each node, as applicable. Connections between nodes are only

shown if the e-value of the best BLAST hit between two sequences is at least as good as the specified e-value cutoff.

*Homology Modeling and in silico Ligand Docking.* The computational procedures were described in detail in an earlier publication.(4) Briefly, homology models of 66 sequences that clustered with experimentally characterized AEEs from *B. subtilis* and *E. coli* have been built using Protein Local Optimization program (PLOP) (commercially available as Prime through Schrödinger LLC). At the time of our modeling there were only 3 AEE structures were available. We have used the structure from *B. subtilis* (1TKK) as the template. This structure was cocrystallized with the dipeptide substrate Ala-Glu and the metal ion  $Mg^{2+}$ ; we retained both of them during modeling. The complete list of homology models is provided in Table S1, including sequence identity to the template, which was  $\sim$ 30% in most cases. We also provide the zdope score for the models (http://modbase.compbio.ucsf.edu/evaluation/), a quality metric for homology models, where a score lower than  $-1.0$  is considered 'good', while a score between 0 and -1 is 'reasonable' (5). The models with the worst zdope scores are, unsurprisingly, those with the lowest sequence identity to the template,  $\sim$ 25%. In cases where crystal structures have been determined, we also report RMSD's for the model overall and for the binding site specifically; it should be kept in mind that the crystal structures were determined subsequently. In cases where co-crystal structures were determined, we provide the RMSD for the best substrate, i.e., those shown in Figure 4.

After the models were built, we have docked an *in silico* library of all 400 L/L-amino acid dipeptides against the active site of all the enzymes that we have modeled using the software Glide-V4.0108 (Schrödinger LLC). The dipeptide library was prepared using LigPrep-v2.0106 (Schrödinger LLC).

*Molecular Graphics Images.* The images in Figures 3 and 4 were constructed using Chimera.(6)

*Assignment of Predicted Specificity Groups*. The predicted specificity groups shown in Figure 1 were assigned by the Jacobson lab in late 2005/early 2006, before experimental results were available, based on the homology models and the docking results. The sequences were first divided into groups according to a phylogenetic tree constructed for the sequences available at the time (see Ref. (1) for the phylogenetic tree with representative sequences shown). The sequence networks shown in Figure 1 and 2 were constructed later using all sequences available in 2011; many of the sequences that were ultimately obtained for experimental characterization were sequences that had not yet been deposited in 2005. However, it can be seen in Figure 1 that the groupings assigned in 2005 track reasonably well with the clustering observed with the clustering obtained with >700 sequences.

The assigned specificities were based primarily on a simple 'consensus' analysis of the docking results, as well as visual inspection of the homology models and selected binding modes. The consensus analysis was based on the hypothesis that 'averaging' the docking results over all of the enzymes in a putative specificity group would lead to more accurate results. That is, docking is notoriously sensitive to even small errors in the precise positioning of side chains, and in this case these errors could in principle be even more pervasive due to the automated nature of the predictions. Thus, while the results from any one homology model might be suspect, the averaged results might more accurately reflect the true specificities.

The consensus results were obtained by analyzing the amino acids found in the Nterminal and C-terminal positions in the top 5% of the hits lists (top 20 hits out of the 400 L/L dipeptides), averaged over the putative specificity clades. The results for the groups containing the characterized AEE's in *B. subtilis* and *E. coli* did show the expected preference for small amino acids in the N-terminal position, and negatively charged in the C-terminal position. Note that the results for the *E. coli* clade were based on models with  $\sim$ 30% sequence identity (to 1TKK). A third group showed a similar pattern, but inspection of several of the models revealed a larger N-terminal pocket that could accommodate amino acids larger than Ala, and as a result, this group was labeled as Xxx-Glu. The docking appears to have not captured this, at least for most of the members of the clade, due to keeping the binding pocket rigid, a constraint that we have relaxed in more recent work.

In the N-terminal position, a small group (6 sequences, of which 4 were 'environmental' sequences) showed a striking preference for positively charged amino acids. The C-terminal position was less consistent, and so the prediction was left as "Lys-Xxx". Overall, however, the results did not show the correct preference for positively charged amino acids in the C-terminal position, as revealed by subsequent experiments, although dipeptides such as Arg-Tyr did show some turnover in the mass spectroscopy assay for the *M. capsulatus* enzyme.

Finally, another fairly small group showed, in the consensus results, divergent specificity primarily at the C-terminal position, with hydrophobic amino acids preferred on average, although not exclusively. Inspection of several of the homology models, however, confirmed hydrophobic binding pockets. Although Ala-Hyd dipeptides were substrates for enzymes in this group that were characterized experimentally, larger hydrophobic amino acids were frequently tolerated or preferred in the N-terminal position, with the exception of the epimerases from *C. hutchinsonii* and from *T. maritima*.

Table i: Prevalence of amino acids in the N-terminal position; top 5% of docking hits, averaged over the putative specificity groups.

Group (final	Small (Ala, Ser,	Negative (Glu,	Positive (Lys,	Hydrophobic
predicted	Thr, Cys, Gly)	Asp)	Arg)	(Met, Leu, Val,
specificity)				Ile, Phe, Trp,
				Tyr)
Ala-Glu	89%	$1\%$	3%	4%
(B. subtilis like)				
Ala-Glu	63%	9%	5%	14%
(E. coli like)				
Xxx-Glu	72%	8%	6%	5%
$Lys-Xxx$	15%	3%	73%	6%
Ala-Hyd	78%	8%	7%	4%

Table ii: Prevalence of amino acids in the C-terminal position; top 5% of docking hits, averaged over the putative specificity groups.



# **Detailed Methods: Crystallography**

*Crystallization and Data Collection for the diepeptide epimerase from B. thetaiotamicron (BT1313)*. Attempts to grow crystals of unliganded BT1313 were unsuccessful. Three different crystal forms of dipeptide liganded BT1313 were grown by the hanging drop method at room temperature, two monoclinic forms complexed with  $Mg^{2+}$  and L-Ala-D-Glu and a monoclinic form complexed with  $Mg^{2+}$  and L-Pro-D-Glu (Table S27).

For the first crystal form of BT1313• $Mg^{2+}$ •L-Ala-D-Glu, the protein solution contained BT1313 (33 mg/mL) in 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, 5 mM  $MgCl<sub>2</sub>$  and 50 mM L-Ala-D-Glu; the precipitant contained 25% PEG 3350 and 0.1 M Hepes (pH 7.5). Crystals appeared in 1-2 days and exhibited diffraction consistent with the space group C2, with two molecules per asymmetric unit. Prior to data collection, the crystals were transferred to a cryoprotectant solution composed of 50% PEG 3350, 0.1 M Hepes (pH 7.5), and 5 mM MgCl<sub>2</sub>; the ligand was not included in cryoprotectant solution.

For BT1313• $Mg^{2+}$ •L-Pro-D-Glu, the protein solution contained BT1313 (27.8 mg/mL) in 20 mM Tris-HCL (pH 7.9), 100 mM NaCl, 5 mM  $MgCl<sub>2</sub>$  and 50 mM L-Pro-L-Glu; the precipitant contained 17% PEG 10000, 0.1 M Bis-Tris (pH 5.5), and 0.1 M ammonium acetate. Crystals appeared in 4 days and exhibited a diffraction pattern consistent with space group C2, with two molecules per asymmetric unit. Prior to data collection the crystals were transferred to cryoprotectant solution composed of 30% PEG 400, 0.1 M Bis-Tris (pH 5.5), 0.1 M ammonium acetate, and 5 mM  $MgCl<sub>2</sub>$ ; the ligand was not included in cryoprotectant solution.

For the second crystal form of  $BT1313 \cdot Mg^{2+} \cdot L$ -Ala-D-Glu, the protein solution contained BT1313 (33 mg/mL) in 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, 5 mM  $MgCl<sub>2</sub>$  and 50 mM L Ala-D-Glu; the precipitant contained 17% PEG 3350, 0.1 M Bis-Tris (pH 5.5), and 0.1 M ammonium sulfate. Crystals appeared in 7-8 days and exhibited a diffraction pattern consistent with space group C2, with two molecules per asymmetric unit. Prior to data collection the crystals were transferred to a cryoprotectant solution composed of their mother liquid and 20% glycerol; the ligand was included in cryoprotectant solution for this crystal form.

After 30 seconds incubation in the cryoprotectant solutions, the crystals of all three complexes were flash-cooled in a nitrogen stream. The diffraction data sets were recorded at the
NSLS X4A beamline (Brookhaven National Laboratory) using an ADSC CCD detector. Diffraction intensities were integrated and scaled with programs DENZO and SCALEPACK.(7) The data collection statistics are given in Table S27.

*Structure Determination and Model Refinement for BT1313*. The structures of the complexes (Table S27) were solved by molecular replacement with fully automated molecular replacement pipeline BALBES(8), using only input diffraction and sequence data. The polypeptide of the L-Ala D/L-Glu epimerase from *Bacillus subtilis* complexed with L-Ala-L Glu (PDB ID 1TKK) was used by BALBES as the template in all three structure determinations. Partially refined structures of all three complexes were the output from BALBES without any manual intervention. Several subsequent iterative cycles of refinement were performed for each crystal form including: manual model rebuilding with TOM, refinement with CNS (9), automatic model rebuilding with ARP (10), and solvent building with the CCP4 suite. Final refinement statistics are provided in the Table S27.

In the final models for one form of the L-Ala-D-Glu and the complex with L-Ala-D-Pro, the N and C terminal residues are disordered; in final model for the second form the L-Ala-D Glu complex, only the N terminal residue is disordered. In each complex, Ala64 in one polypeptide lies in the disallowed region of Ramachandran plot; this residue is located at the tip of the 20s loop. In each active site, well-defined electron density is observed for the dipeptide ligand and the  $Mg^{2+}$  ion.

In the first crystal form of BT1313•Mg<sup>2+</sup>•L-Ala-D-Glu (Table S27, column 1), the carboxylate group of the L-Ala-D-Glu ligand is located in the second coordination sphere of the  $Mg^{2+}$ , hydrogen bonded to waters that are coordinated to the  $Mg^{2+}$ . In addition, the putative acid/base catalysts, the N $\xi$  atoms of Lys200 and Lys298, are too distant from the  $\alpha$ -carbon of the Glu moiety of the ligand to catalyze the 1,1 proton transfer reaction, with the distances 4.7 and 4.9 Å, respectively. Therefore, this structure is necessarily that of a nonproductive complex.

The structure of the BT1313• $Mg^{2+}$ •L-Pro-D-Glu (Table S27, column 2) complex is also that of a nonproductive complex: the carboxylate group of the ligand is in the second coordination sphere of the Mg<sup>2+</sup>, with the consequence that the N $\xi$  atoms of Lys200 and Lys298 are too distant from the  $\alpha$ -carbon of the Glu moiety of the ligand to catalyze the 1,1 proton transfer reaction.

In the second crystal form of BT1313• $Mg^{2+}$ •L-Ala-D-Glu (Table S27, column 3), the two polypeptides in the asymmetric unit have different coordination geometries for the dipeptide ligand. In polypeptide A, the geometry is similar to that observed in the first crystal form. However, in the polypeptide B, the carboxylate group of the L-Ala-D-Glu ligand is a bidentate ligand of the Mg<sup>2+</sup>. The N $\xi$  atoms of Lys200 and Lys298 are each located ~4 Å from the  $\alpha$ carbon of the Glu moiety of the ligand and can approach the  $\alpha$ -carbon atom as to catalyze the 1,1 proton transfer reaction.

*Crystallization and Data Collection for the dipeptide epimerase from C. hutchinsonii (CHU2140).* Initial attempts to obtain diffracting crystals of CHU2140 were unsuccessful both in the presence and absence of dipepdide ligands. One month after the initial setup of the Hampton Research Index Screen, birefringent precipitate was discovered in conditions #42 and #70. Optimization of #42 was carried out by varying the chain-length of the PEG precipitant, pH of the crystallization condition, and the temperature of incubation environment. After optimization, two forms of fused rod-shaped monoclinic crystals of CHU2140 were obtained, complexed with

 $Mg^{2+}$  and D-Ala-L-Ala, and with  $Mg^{2+}$  and D-Ala-L-Val. The dipeptide-liganded crystals were grown by the hanging drop vaporization method at 4°C.

For the crystals of CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Ala, the protein solution contained CHU2140 (40 mg/mL) in 20 mM Hepes (pH 8.35), 100 mM NaCl, 5 mM  $MgCl<sub>2</sub>$ , 10% glycerol, and 20 mM D-Ala-L-Ala; the precipitant contained 10% PEG 4000 and 0.1 M Na-citrate (pH 4.0). Crystals appeared in 7-10 days and exhibited diffraction consistent with the space group  $P2<sub>1</sub>$ , with nine molecules per asymmetric unit. Prior to data collection, the crystals were transferred to a cryoprotectant solution composed of 10% PEG 4000, 25% ethylene glycol and 0.1 M Na-citrate (pH 4.0); the ligand was not included in crypoprotectant solution.

For the crystals of CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Val, the protein solution contained CHU2140 (40 mg/mL) in 20 mM Hepes (pH 8.35), 100 mM NaCl, 5 mM MgCl<sub>2</sub>, 10% glycerol, and 20 mM D Ala-L-Val; the precipitant contained 12% PEG 10000 and 0.1 M Na-citrate (pH 4.0). Crystals appeared in 7-10 days and exhibited diffraction consistent with the space group P21, with nine molecules per asymmetric unit. Prior to data collection, the crystals were transferred to a cryoprotectant solution composed of 12% PEG 10000, 30% ethylene glycol and 0.1 M Na-citrate (pH 4.0); the ligand was not included in crypoprotectant solution.

After 30 seconds of incubation in the cryoprotectant solution, the crystals were flashcooled in liquid nitrogen. The diffraction data set for CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Ala crystal was recorded at LS-CAT (Sector 21 ID-F, Advanced Photon Source, Argonne, IL) using a MAR 225 CCD detector. The diffraction data set for CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Val crystal was recorded at LS-CAT (Sector 21 ID-G, Advanced Photon Source, Argonne, IL) using a MAR 300 CCD detector. Diffraction intensities were integrated and scaled with XDS (11). The data collection statistics are given in Table S28.

*Structure Determination and Model Refinement for CHU2140*. The structures of CHU2140 in complex with dipeptide substrates, and  $Mg^{2+}$  were solved by molecular replacement with PHASER (12), using input diffraction, sequence data and the atomic coordinates of the L-Ala-D/L-Glu epimerase from *Bacillus subtilis* (PDB ID 1TKK) modified with CHAINSAW (13) to trim non-identical residues to Ala. The partial solution from PHASER was then subjected to automated model building with *AutoBuild* in PHENIX (14), followed by multiple iterative cycles of manual and automated refinement with COOT (15) and REFMAC5 (16). Final refinement statistics are provided in Table S28. The asymmetric unit of both liganded structures of CHU2140 consists of nine monomers, some of which are less ordered than others. The capping domain loops involved in substrate recognition are well ordered in all monomers. Electron density for the dipeptide ligand and  $Mg^{2+}$  ion is observed in all nine polypeptides.

The structure of CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Ala has well defined active sites in all nine monomers. However, the substrate molecule has well-defined density and acceptable B-factors only in polypeptide A. The N $\xi$  atoms of putative acid-base catalysts Lys162 and Lys265 are within  $\sim$ 4 Å of the  $\alpha$ -carbon of L-Ala substrate moiety, positioned in proper distance to facilitate 1,1-proton transfer (Figure 4).

The structure of CHU2140 $\cdot$ Mg<sup>2+</sup> $\cdot$ D-Ala-L-Val has similarly ordered active site architectures in all nine monomers. Much like with the previous complex, only polypeptide B contains well-ordered density for the dipeptide substrate with B-factors in the acceptable range for the fitted ligand. The N $\xi$  atoms of putative acid-base catalysts are within  $\sim$ 4 Å of the  $\alpha$ carbon of L-Val moiety, conferring this structure too as a catalytically productive complex.

The active site for both crystal forms contains a dipeptide substrate, which is essentially in rapid equilibrium. However, due to resolution constraints, it is unfeasible to give an unbiased assessment as to which stereoisomer is predominantly bound in the active sites. Therefore, ligand-fitting into the electron density was performed with D-Ala-L-Xxx dipeptide for both crystal forms.

### *Crystallization and data collection for the dipeptide epimerase from E. faecalis (EF1511).*

The unliganded crystal form was grown by the hanging drop method at room temperature for the dipeptide epimerase from *Enterococcus faecalis*. The protein solution contained the protein (44 mg/mL) in 20 mM Tris (pH 7.9), 100 mM NaCl, and 10 mM  $MgCl<sub>2</sub>$ . The precipitant contained 2.0 M ammonium sulfate,  $0.1$  M Hepes (pH 7.5), and 10 mM MgCl<sub>2</sub>. Crystals appeared in 3 days and exhibited diffraction consistent with space group R3, with eight molecules of the protein per asymmetric unit.

Four different crystal forms were grown by the hanging drop method at room temperature for the dipeptide epimerase from *E. faecalis* liganded with dipeptides: (1) The complex EF1511·L-Ile-L-Tyr, (2) The complex EF1511·L-Leu-L-Tyr, (3) The complex EF1511·L-Ser-L-Tyr, and (4) The complex EF1511·L-Arg-L-Tyr. The protein solutions for all four cococrystallizations contained the protein (53 mg/mL), 20 mM Tris (pH 7.9), 100 mM NaCl, 40 mM  $MgCl<sub>2</sub>$ , and the corresponding dipeptide (40mM).

(1) For EF1511·L-Ile-L-Tyr complex, the precipitant contained 1.4 M Sodium citrate, and 0.1 M Hepes (pH 7.5). Crystals appeared in 5 days and exhibited diffraction consistent with space group C2, with eight molecules of the complex per asymmetric unit.

(2) For complexes EF1511·L-Leu-L-Tyr and EF1511·L-Arg-L-Tyr, the precipitant contained 1.8 M ammonium sulfate, and 0.1 M Hepes (pH 7.5). In both cases the crystals appeared in 7 days and exhibited diffraction consistent with space group R3, with eight molecules of the corresponding complex per asymmetric unit.

(3) For EF1511·L-Ser-L-Tyr complex, the precipitant contained 1.6 M sodium citrate, and 0.1 M Hepes (pH 7.5). Crystals appeared in 4 days and exhibited diffraction consistent with space group R3 with eight molecules of the complex per asymmetric unit.

Prior to data collection, the crystals of all 5 dipeptide epimerase EF1511 forms (Table S26) were transferred to cryoprotectant solutions composed of their mother liquids and 20% glycerol and flash-cooled in a nitrogen stream. All 5 X-ray diffraction data sets were collected at the NSLS X4A beamline (Brookhaven National Laboratory) on an ADSC CCD detector. Diffraction intensities were integrated and scaled with programs DENZO and SCALEPACK (7). The data collection statistics are given in Table S26.

*Structure determination and model refinement for the dipeptide epimerase from E. faecalis (EF1511)*

All 5 EF1511 structures (Table S26) were solved by molecular replacement with fully automated molecular replacement pipeline BALBES (8), using only input diffraction and sequence data. The protein part of the dipeptide epimerase from *Bacillus subtilis* liganded with L-Ala-L-Glu (PDB ID 1TKK) was used by BALBES as a search template. Partially refined structures of all 5 EF1511 crystal forms were the outputs from BALBES. Subsequently, several iterative cycles of refinement were performed for each crystal form including: the model rebuilding with COOT (15), refinement with CNS (9), and automatic model rebuilding with ARP  $(10).$ 

Final crystallographic refinement statistics for all determined EF1511 structures are provided in the Table S26.

## *Crystallization and data collection for the dipeptide epimerase from M. capsulatus (MCA1834).*

Initial crystallization conditions were determined using the sparse matrix method. All crystals were grown by the hanging drop vaporization method at 4° C. One week after the setup of the Hampton Research Index Screen, diffracting crystals were obtained in condition #77 in the presence of 20x molar excess of L-Arg-L-Lys. Optimization of #77 was carried out as described for CHU2140. After optimization, an additional form of fused plate-like crystals were obtained using similar conditions but in the presence of  $Mg^{2+}$ .

For the crystals of MCA1834• $Mg^{2+}$ •L-Arg-D-Lys, the protein solution contained MCA1834 (12 mg/mL) in 50 mM Hepes (pH 8.0), 100 mM KCl, 5 mM MgCl<sub>2</sub>, and 20 mM L-Arg-L-Lys; the precipitant contained  $25\%$  PEG 3500, 200 mM Li<sub>2</sub>SO<sub>4</sub>, and 100 mM Tris-HCl (pH 8.5). Crystals appeared in 5 days and exhibited diffraction consistent with the space group I213, with five molecules per asymmetric unit. Prior to data collection, the crystals were transferred to a cryoprotectant solution composed of 30% PEG 3350, 200 mM M  $Li<sub>2</sub>SO<sub>4</sub>$ , and 100 mM Tris-HCl (pH 8.5) and vitrified by direct immersion into liquid nitrogen. The ligand was not included in crypoprotectant solution.

For the crystals of MCA1834•Mg<sup>2+</sup>, the protein solution contained MCA1834 (10) mg/mL) in 50 mM Hepes (pH 8.0), 100 mM KCl, 5 mM  $MgCl<sub>2</sub>$ , and 5 mM L-Arg-L-Lys; the precipitant contained 10% PEG 4000, 200 mM MgSO4 and 100 mM MES (pH 5.5). Crystals appeared in two weeks and exhibited diffraction consistent with the space group  $P2<sub>1</sub>$ , with six molecules per asymmetric unit. Prior to data collection, the crystals were transferred to a cryoprotectant solution composed of 12.5% PEG 4000, 25% glycerol, 200 mM MgSO4, and 100 mM MES (pH 5.5) and vitrified as above.

All data were collected on crystals that were maintained at 100K. The diffraction data set for MCA1834•Mg<sup>2+</sup>•L-Arg-D-Lys crystal was recorded at LS-CAT (Sector 21 ID-G, Advanced Photon Source, Argonne, IL) using a MAR 300 CCD detector. The diffraction data set for MCA1834•Mg<sup>2+</sup> crystal was recorded at LS-CAT (Sector 21 ID-D, Advanced Photon Source, Argonne, IL) using a MAR 300 CCD detector. Diffraction intensities were integrated and scaled with XDS package (11). The data collection statistics are given in Table S29.

## *Structure determination and model refinement for MCA1834*.

The structures of MCA1834 in complex with L-Arg-D-Lys, and  $Mg^{2+}$  were solved by molecular replacement as described for CHU2140. Final refinement was carried out using PHENIX (14). Refinement statistics are provided in Table S29. Of the five molecules in the crystallographic asymmetric unit, all polypeptides contain good electron density for the L-Arg portion of the dipeptide ligand, only polypeptides B, C and E contain well-ordered density for the entire dipeptide substrate. Electron density at the active sites were consistent with the epimerized L-Arg-D-Lys isoform of the substrate. The magnesium ion sits low in the metal binding pocket and has unusually long distances to the carboxylate group of the substrate as well as its respective binding residues, perhaps caused by an elongated substrate molecule. There also seems to be an alternative quaternary Glu242 metal binding ligand that is positioned in an appropriate distance to the metal ion upon substrate binding. The  $N\xi$  atoms of Lys162 and Lys266 are positioned both within  $\sim$ 4 Å of the  $\alpha$ -carbon of the D-Lys portion of the substrate to facilitate acid-base catalysis.

The structure of MCA1834 $\cdot$ Mg<sup>2+</sup> was solved in a similar manner to that of the dipeptide complexed form of the enzyme. All six monomers of the asymmetric unit are almost identical but are missing the 20s loop portion that is involved in substrate binding. The magnesium ion coordination to the metal binding ligands for this crystal form is more consistent with that observed for other dipeptide epimerase group members. The active site for the enzyme is filled with water molecules, rather than the substrate. Another observable change in addition to the metal-binding site can be seen for the Asp319 residue of the Asp-X-Asp motif. Compared to the dipeptide complexed structure, Asp319 is now rotated  $\sim 80^\circ$  about the  $\beta$ -carbon of that residue to make a tight contact with a cluster of water molecules away from the site that would otherwise be occupied by the a-ammonium group of the dipeptide substrate.

Although multiple attempts were made to obtain crystals in the presence of ligands that are catalytically more efficient in enzyme assays, no diffraction quality crystals were produced.

# *Crystallization and structure determination of Francisella philomiragia ATCC 25017 (GI:167627873, NYSGRC-200555)*.

The dipeptide epimerase from *F. philomiragia* (Fphi1647) was crystallized by sitting drop vapour diffusion in 96-well *Intelliplates* (Art Robbins Instruments). Protein (2µl, 10 mg/mL, 20 mM HEPES pH 7.5, 150 mM NaCl, 10% Glycerol, 0.1% Sodium Azide, 0.5 mM TCEP) was combined with reservoir solution  $(2 \mu l, 2M (NH_4)_2SO_4, 100 \text{ mM NaC}$  trate, 200 mM KNaTartrate pH 5.6) and equilbrated against 70 µl of the same reservoir at 20 degrees C. Crystals grew as tetragonal bipyramids (0.2 x 0.2 x 0.2mm) over a period of 2-6 days and belong to space group  $P4_12_12$  with cell dimensions of a=b=121, c=149.

For the initial structure determination crystals were soaked in 2.4 M ( $NH<sub>4</sub>$ )<sub>2</sub>SO<sub>4</sub>, 100 mM NaCitrate, 200 mM KNaTartrate pH 5.6, 20% glycerol prior to vitrification by immersion in liquid nitrogen. The L-Ala-D/L-Glu complex was determined from crystals that were soaked for 30 minutes in 2.4 M (NH4)2SO4, 100 mM MES pH 6.0, 20% glycerol, 10 mM L-Ala-D/L-Glu, 50 mM MgSO4. All data were collected at the 31-ID beamline (LRL-CAT), Advanced Photon SOURCE, integrated with MOSFLM (17) and scaled with SCALA (18). Refinement statistics are reported in Table S30.

The structure of Fphi1647 was determined by selenomethionine single anomalous dispersion collected at the selenomethionine anomalous peak. The determination of selenomethionine positions, calculation of solvent-flattened phases, and the autofitting of the majority of the structure were performed in PHENIX (14). Iterative cycles of manual fitting followed by refinement against the data utilized COOT (15) and PHENIX, respectively. Waters were added to Fo-Fc peaks greater than 3.5 sigma that were within hydrogen bonding distance to a potential partner. Translation-libration-screw refinement (TLS (19)) was utilized during the final rounds with individual bodies determined by the TLS-server. The determination of the L or D form of glutamic acid in the dipeptide complex utilized careful analysis of 2Fo-Fc and Fo-Fc maps generated by refined structures with and without the forms of the dipeptide.

There is a dimer in the asymmetric unit that is consistent with the molecular dimer suggested by gel filtration chromatography (data not shown), and is similar to one of the dimer interfaces seen in the *B. subtilus* octamer. The initial Fphi1647 structure bound a tartrate molecule in subunit A and a sulfate in subunit B (3R0K) but was devoid of Mg. Density for the 20's loop in subunit A was not of sufficient quality to build a molecular model, but was

suggestive of an open conformation, while the 20's loop in subunit B was visible and closed over the active site.

Removal of dicarboxylates from the soaking solution and inclusion of 10 mM L-Ala-L-Glu and 50 mM Mg resulted in a dipeptide bound structure (3R1Z), though no Mg was found. The two active sites are unique in their interactions with the bound ligands. In subunit A the density was consistent with a bound L-Ala-L-Glu, while in subunit B the density was consistent with L-Ala-D-Glu. In subunit A, L-Ala-L-Glu is bound with the anomeric carbon 3.5 Å from Lys164 and 4.3 Å from Lys269 the presumed active site acid and/base. In contrast, in subunit B, L-Ala-D-Glu is bound in a similar fashion but is 3.7 Å from Lys164 and 3.4 Å from Lys269. In both subunits the amine of L-Ala is coordinated by the side chains of Asp321, Asp323 and Ser137, while the amide of the dipeptide is coordinated by the backbone carbonyl of Cys297. In addition the side chain carboxylate makes a salt bridge with Arg26 of the 20s loop resulting in a closed loop structure in both subunits. Utilizing the Mg-bound structure as a model, the binding conformation of the dipeptide in subunit A would be monodentate with a ligand distance of 3 Å and in subunit B would be bidentate with ligand distances of 2.5 and 2.8 Å. The differential binding of ligands to the individual subunits is most likely due to the dissimilar crystal contacts of the subunits restricting the flexibility of the protein.

# *Crystallization and structure determination of the dipeptide epimerase from Herpetosiphon aurantiacus*

The target was expressed as a full-length protein supplemented with the C-terminal His-TAG (EGHHHHHH). Following the standard expression and purification protocols, the initial solution was concentrated to about 37 mg/mL of protein by using 30K Amicon centrifugal

microtubes. The protein was crystallized by the sitting drop vapor diffusion method. In brief, 1 microliter of a protein solution was mixed with an equal volume of a mother liquor which consists of 150 mM KBr and 30% PEG2000 MME as precipitants and equilibrated at room temperature against the same mother liquor in clear tape sealed 96-well crystallization plates. The large (around 1 mm in diameter) single diamond-shaped crystal was observed in one of the drops after two months of incubation. The crystal was collected by the Hampton Research cryogenic loop, quickly transferred in liquid nitrogen, and stored frozen in liquid nitrogen until X-ray analysis and data collection. The X-ray diffraction data from the frozen crystal were collected on the Beamline X29A (NSLS, Brookhaven National Laboratory) at wavelength of 1.08 Å. The analysis of diffraction images has revealed the polycrystalline nature of this crystal. However, since it was quite sizable, we have examined diffraction patterns coming from different parts of the crystal and finally found out that its triangular tip represents a single crystal suitable for data collection. The X-ray diffraction data were collected to resolution of 2.07 Å, then they were processed and scaled using HKL2000 program package (7). The crystal structure was solved by molecular replacement using the coordinates for 1JPM (PDB) as a search model. The structure was refined by REFMAC 5.03 (CCP4 Program package (16)) and the model was fixed manually using COOT (15) visualization and refinement software. The data collection and refinement statistics for this structure are shown in the Table S31.

### **References**

1. Song L*, et al* (2007) Prediction and assignment of function for a divergent N-succinyl amino acid racemase*. Nat Chem Biol* 3: 486-491.

2. Pegg SC*, et al* (2006) Leveraging enzyme structure-function relationships for functional inference and experimental design: The structure-function linkage database*. Biochemistry* 45: 2545-2555.

3. Cline MS*, et al* (2007) Integration of biological networks and gene expression data using cytoscape*. Nat Protoc* 2: 2366-2382.

4. Kalyanaraman C*, et al* (2008) Discovery of a dipeptide epimerase enzymatic function guided by homology modeling and virtual screening*. Structure* 16: 1668-1677.

5. Shen MY & Sali A (2006) Statistical potential for assessment and prediction of protein structures*. Protein Sci* 15: 2507-2524.

6. Pettersen EF*, et al* (2004) UCSF chimera--a visualization system for exploratory research and analysis*. J Comput Chem* 25: 1605-1612.

7. Otwinowski Z & Minor W (1997) in *Methods in Enzymology,* eds Carter CWJ, Sweet RM, Abelson JN & Simon MI, Academic Press (New York), pp 307-326.

8. Long F, Vagin AA, Young P & Murshudov GN (2008) BALBES: A molecular-replacement pipeline*. Acta Crystallogr D Biol Crystallogr* 64: 125-132.

9. Brunger AT*, et al* (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination*. Acta Crystallogr D Biol Crystallogr* 54: 905-921.

10. Lamzin VS & Wilson KS (1993) Automated refinement of protein models*. Acta Crystallogr D Biol Crystallogr* 49: 129-147.

11. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants*. J Appl Crystal* 26: 795-800.

12. McCoy AJ*, et al* (2007) Phaser crystallographic software*. J Appl Crystallogr* 40: 658-674.

13. Stein N (2008) CHAINSAW: A program for mutating pdb files used as templates in molecular replacement*. J Appl Crystal* 41: 641-643.

14. Adams PD*, et al* (2002) PHENIX: Building new software for automated crystallographic structure determination*. Acta Crystallogr D Biol Crystallogr* 58: 1948-1954.

15. Emsley P, Lohkamp B, Scott WG & Cowtan K (2010) Features and development of coot*. Acta Crystallogr D Biol Crystallogr* 66: 486-501.

16. Murshudov GN, Vagin AA & Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method*. Acta Crystallogr D Biol Crystallogr* 53: 240-255.

17. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data*. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography* 26:

18. Evans P (2006) Scaling and assessment of data quality*. Acta Crystallogr D Biol Crystallogr*  62: 72-82.

19. Winn MD, Isupov MN & Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement*. Acta Crystallogr D Biol Crystallogr*  57: 122-13